The United Kingdom and the United States have concluded a landmark bilateral deal that will ensure zero duties on British pharmaceutical shipments being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to boost funding on medicines through the NHS. This move guarantees that tariffs on these key products will remain at nothing for a timeframe of the next three years.
This agreement comes after earlier warnings to significantly raise import taxes on branded drug imports, with potential rates floated as high as double the cost.
"This agreement between the Britain bolsters the worldwide climate for innovative medicines and introduces much-needed balance to transatlantic medicine commerce," a release noted.
Commercial Impact
Drugs constitute one of the UK's most significant goods shipped to the US, which is easily the largest buyer for large companies like GSK and AstraZeneca.
Trade data reveal that in the year prior to last September, the UK sold drugs totaling billions to the US. This amount made up 17.4% of British export trade in that timeframe.
"This agreement protects employment, stimulates investment and sets the stage for the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Specific UK Commitments
The deal entails several notable pledges from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a target to increase total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The amount manufacturers must refund to the NHS to control costs will be capped at fifteen percent. Last year, refunds were more than twenty percent.
Recent Tensions
This agreement follows a ongoing dispute between the drug companies and the British authorities over drug pricing and regulatory access.
These tensions were exacerbated by assertions that US patients were paying significantly more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or abandoned, while substantial funding commitments have been pledged toward projects in the United States.
One official publicly accepted that the NHS had to spend more on drugs, noting that its expenditure on drugs had declined as a percentage of its total funding over the previous ten-year period.
